医保买药比自费更贵？国家医保局严查整治“阴阳价格”

Core Viewpoint - The National Healthcare Security Administration (NHSA) has issued a notice to strengthen the monitoring and handling of "dual pricing" in designated retail pharmacies, aiming to regulate industry practices and protect the safety of medical insurance funds and the rights of insured individuals [1] Group 1: Regulatory Actions - The NHSA has explicitly defined "dual pricing" as the practice where designated retail pharmacies charge insured patients a higher price for the same medication compared to non-insured patients [1] - The notice indicates that such pricing practices by designated pharmacies may constitute price fraud, violating the service agreement that prohibits unfair and discriminatory pricing against insured individuals [1] Group 2: Industry Implications - The NHSA's directive emphasizes the need for strict investigation and handling of pharmacies engaging in dual pricing, which could lead to significant regulatory scrutiny within the retail pharmacy sector [1] - This move is expected to enhance the integrity of the healthcare system and ensure fair pricing practices, potentially impacting the operational strategies of designated retail pharmacies [1]